Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from thyroid C cells, comprising approximately 5% of all thyroid cancers.
• MTC typically displays aggressive behavior, frequently presenting with lymph node metastasis, and is strongly associated with germline RET mutations (nearly 100% penetrance).
• Activating RET mutations are prevalent in both hereditary (over 90%) and sporadic (40%) MTC, leading to FDA approval of RET-targeting multikinase inhibitors like vandetanib and cabozantinib.

Purpose of the Study:

• To review the fundamental pathology of medullary thyroid carcinoma.
• To provide an update on recent research advancements in MTC, focusing on molecular events.
• To highlight the emerging role of microRNAs (miRNAs) in MTC pathogenesis and therapeutic potential.

Main Methods:

• Literature review of medullary thyroid carcinoma pathology.
• Analysis of recent studies on molecular mechanisms in MTC.
• Synthesis of findings on microRNA deregulation in MTC.

Main Results:

• RET mutations are key drivers in a significant proportion of MTC cases, informing targeted therapy development.
• Despite targeted therapies, individual variations in MTC tumor behavior and treatment response necessitate further molecular investigation.
• Numerous microRNA (miRNA) deregulations have been identified in MTC, suggesting their potential as prognostic markers and therapeutic targets.

Conclusions:

• Understanding the molecular heterogeneity of MTC, including RET-driven and non-RET-driven tumors, is crucial for personalized treatment.
• MicroRNAs represent a promising area of research for unraveling MTC complexity and developing novel therapeutic strategies.
• Continued investigation into MTC molecular pathology, including miRNA roles, is essential for improving patient outcomes.